UBS Maintains a 'Neutral' on Baxter International (BAX); Healthy Q1

UBS maintains a 'Neutral' on Baxter International (NYSE: BAX) price target lowered from $66 to $64.

Analyst, Rajeev Jashnani, said, "BAX posted a very healthy 1Q12 w/ strength in both BioScience & Medical Products. However, despite a limited impact to published estimates, it is evident that the HyQ delay has taken a bite out of sentiment, as the product that enabled share gain/upside to numbers is removed from the equation, at least in the near-term. We look forward to continued good op performance in 2012 w/key news flow on Alzheimer’s/Recombinants pipe across 2013 & expanded plasma capacity in 2H13."

For an analyst ratings summary and ratings history on Baxter International click here. For more ratings news on Baxter International click here.

Shares of Baxter International closed at $54.18 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities